University of Maryland Baltimore

BALTIMORE, Oct. 28, 2024 /PRNewswire/ -- Margaret M. McCarthy, PhD, an internationally-recognized neuroscientist, who is the James and Carolyn Frenkil Dean's Endowed Professor in the University of Maryland School of Medicine's Department of Pharmacology, Physiology, and Drug Development, and Director of the University of Maryland - Medicine Institute of Neuroscience Discovery (UM-MIND), has been elected as a new member of the National Academy of Medicine. Election to the NAM is considered one of the highest honors in health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. The Academy recognized Dr. McCarthy for her influential research on the cellular mechanisms that establish sex differences in developing brains, and for being the first to discover a critical role of the immune system in determining sex differences and the impact of infection and inflammation on neuroanatomical and behavioral outcomes. Her research illuminates novel mechanisms by which male and female brains become differentially vulnerable to the impact of injury and inflammation, which can have lifelong consequences for risk of neuropsychiatric and neurological disorders. NAM elected 90 regular members and 10 international members during its annual meeting. The newly elected members bring NAM's total membership to more than 2,400, which includes nearly 200 international members. Current NAM members elect new members through a process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health. A diversity of talent among NAM's membership is assured by its Articles of Organization, which stipulate that at least one-quarter of the membership is selected from fields outside the health professions -- for example, from such fields as law, engineering, social sciences, and the humanities. "Dr. McCarthy has been instrumental in shaping the study of neuroscience and our understanding of how the brain develops differently in males and females," said Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM, and Vice President for Medical Affairs at University of Maryland, Baltimore. " Her seminal research on the influence of steroid hormones on the developing brain, and studies of inflammatory and immune-mediated sex differences have played a major role in the treatment of developmental neuropsychiatric disorders with a gender bias." Major Discoveries on Sex Differences and the Brain As a leading neuroscientist, Dr. McCarthy has made significant discoveries related to sex differences and the brain. Her more than 270 scientific publications have been cited more than 18,000 times in more than 11,000 articles, with the NIH providing her with $28 million in continuous funding over the past 30 years. Dr. McCarthy was the first to discover a critical role of the immune system in determining sex differences and the impact of infection and inflammation on neuroanatomical and behavioral outcomes, which provided mechanistic insights into the higher prevalence of autism spectrum disorders and schizophrenia in boys and men. She also conducted some of the first studies illuminating the molecular and genetic mechanisms that feminize or masculinize the developing brain. Dr. McCarthy's research has revealed both naturally occurring variations and points of vulnerability and nodes for intervention in the treatment of developmental neuropsychiatric disorders with a gender bias. Her work is leading to new innovations in policies by the NIH and the FDA mandating that preclinical research and drug dosing take into account the potential influence of sex and gender on outcomes. The impact of these policy shifts will include new guidelines for the treatment of both men and women that incorporate the importance of sex as a biological variable. Longtime Academic Leader Dr. McCarthy joined the UMSOM faculty in 1993 as a Assistant Professor in the Department of Physiology. In 2002 she was appointed Assistant Dean of Graduate Studies at the University of Maryland, Baltimore, serving as the inaugural Director of the graduate Program in Life Sciences, as well as being named Associate Director of the Program in Neuroscience at the graduate school. Dr. McCarthy was named Chair of the Department of Pharmacology at the medical school in 2011, and became the Director of the Program in Neuroscience in 2019. In 2023, as the School of Medicine merged the departments of Physiology and Pharmacology to create the new Department of Pharmacology, Physiology, and Drug Development, Dr. McCarthy transitioned from her role as Chair to become the inaugural Director of the new University of Maryland - Medicine Institute of Neuroscience Discovery (UM-MIND). Formed in 2023, the Institute conducts translational research of the brain and fosters collaboration between basic and clinical neuroscientists. "It is a tremendous honor to receive this recognition from the National Academy of Medicine," said Dr. McCarthy. "I have spent most of my career at the University of Maryland School of Medicine and owe this success to the many trainees, colleagues, friends, and leaders who have supported and challenged me along the way." In addition to her research and academic positions, Dr. McCarthy is past President of the Organization for the Study of Sex Differences, a member of the Dana Alliance on Brain Research, and a Fellow of the American Association for the Advancement of Science. She has served as Associate Editor of the Journal Hormones and Behavior since 2004, and as an Advisory Board Member of eNeuro since 2015. Dr. McCarthy also served as Associate Editor of the Journal of Neuroscience from 2007 to 2011, and was Editor of Endocrinology from 2008 to 2013. The University of Maryland, Baltimore recognized Dr. McCarthy as Researcher of the Year in 2016, and she has received numerous other awards over the course of her career, including the Patricia Sokolove Outstanding Mentor Award from the Graduate Student Association, and being named one of Maryland's Top 100 women by the Maryland Daily Record. Other UMSOM faculty members who have been elected to the National Academy of Medicine include: William Carpenter, Howard Goldman, E. Albert Reece, Paul Stolley, Donald Wilson, Theodore Woodward, Claire Fraser, Robert Gallo and Kirsten Lyke. About the National Academy of Medicine Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the National Academy of Medicine addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors. NAM works alongside the National Academy of Sciences and the National Academy of Engineering to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies of Sciences, Engineering, and Medicine also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding of STEMM. With their election, NAM members make a commitment to volunteer their service in National Academies activities. About the University of Maryland School of Medicine Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $500 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu Provided by Newswise, online resource for knowledge-based news at SOURCE University of Maryland School of Medicine WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (CRO), for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMB). The study will examine the organ/tissue specificity of the SPU-16 peptide in an experimental autoimmune encephalomyelitis (EAE) protocol, is the most commonly used experimental model for MS. The peptide’s proven ability to target inflamed epithelium suggests that it can be used as a targeted drug delivery tool to address inflammation in the spinal cord. “We are excited to launch this new study of our novel CNS homing peptide under the management of WuXi AppTec, one of the largest CROs in Asia and globally,” said Silo CEO Eric Weisblum.1 “Designed to cross the blood-brain barrier and target damaged tissue and inflammation, SPU-16 has been shown to enhance the therapeutic effect of current and future therapeutics while decreasing the toxicity of the drugs. While we are currently investigating the peptide for MS, it could provide similar benefits for multiple neuroinflammatory pathologies.” MS, a human inflammatory demyelinating disease, is one of the most widespread disabling neurological conditions of young adults.2 The global multiple sclerosis drugs market size is projected to grow at a compound annual growth rate (CAGR) of 7.9% from $21.2 billion in 2024 to $38.9 billion by 2032.3 About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information, visit www.silopharma.com and connect on social media at LinkedIn , X , and Facebook . Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law. Contact 800-705-0120 investors@silopharma.com 1 BAIPHARM, Top 10 CROs With the Highest Revenues in 2023, April 20242 Healthline, Multiple Sclerosis: Facts, Statistics, and You3 Fortune Business Insights, Multiple Sclerosis Drugs Market Size, Share & Industry Analysis…, July 2024

BALTIMORE, July 12, 2024 /PRNewswire/ -- University of Maryland Faculty Physicians has entered into an agreement to lease 17,000 square feet of space at The Village at Mondawmin, which would establish a new community "health village," University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, and Faculty Practice President William F. Regine, MD, announced today. It is part of a larger effort to work in partnership with the West Baltimore community to develop and implement health care delivery based on neighborhood needs and to improve patient access to healthcare. Continue Reading Rachel L. Hoover, MS, MBA The Faculty Practice group of UMSOM is comprised of 1,300 physicians and providers in more than 80 medical specialties and subspecialties who lead the clinical education of future generations of providers; faculty are also involved in advanced research and clinical trials, while also delivering state-of-the-art clinical care to patients throughout Maryland. "We are excited to create a health village that will provide medical, dental, and ancillary services to the Mondawmin community in a clean, safe, and peaceful space that promotes equity, health, and wellness," said Esa M. Davis, MD, MPH,Associate Vice President for Community Health at the University of Maryland, Baltimore (UMB) and Senior Associate Dean for Population and Community Medicine at UMSOM . "We want everyone in the community to have a doctor and medical team they can work with and build a long-term relationship with to improve their health and support their well-being." When the new Faculty Practice opens at The Village at Mondawmin next year, it will offer primary care services aimed at prevention including pediatrics, yearly wellness visits, and geriatrics. Faculty physicians will also offer advanced primary care services and subspecialty services such as cardiology, endocrinology and gastroenterology. Nutrition counseling, prenatal care, treatment of HIV and other infectious diseases, and mental health services will also be provided. "Social determinants of health--where people live, learn, work, and play --account for 50 to 60 percent of health outcomes and are a key driver of disparities in health," said Dean Gladwin. "This partnership is a central part of our joint strategic plan and shared mission of the UM School of Medicine and the UM Medical Center, and will enable us to provide accessible and equitable healthcare by bringing our physicians directly into the West Baltimore communities." The Village at Mondawmin redevelopment is being undertaken by TouchPoint Empowerment Center, LLC, an entity owned personally by Tim Regan, President & CEO of The Whiting-Turner Contracting Company. "We're thrilled to have the University of Maryland Faculty Practice on board as a tenant at The Village at Mondawmin," said Mr. Regan. "Their world-class physicians and providers will significantly enhance the medical services available to the people of West Baltimore, reinforcing the Village's role as a comprehensive hub for health, wellness, and community resources. It's exciting to see this project continue to gain momentum as we welcome tenants who are committed to making a difference in this special community." The University of Maryland Faculty Practice joins CareFirst BlueCross BlueShield, Whiting-Turner, an expanded and relocated TouchPoint Baltimore, and Edenbridge PACE of West Baltimore as future tenants in the building. These tenants represent 75 percent of the leasable space in the project. Discussions are ongoing with other potential tenants, including a daycare provider, restaurants, and retail establishments. Interested businesses are invited to consider joining the community. The Village at Mondawmin leadership along with community leaders will continue to work to lease space to tenants that fill important community needs. "Our goal is to provide the highest quality of care to our community in West Baltimore by meeting them where they work and live," said Dr. Regine. "By establishing this community health village, we want to ensure that every resident has easy access not only to medical services but to prevention and health education programs that help incorporate a person's individual culture and customs into healthier lifestyle choices." Rachel Hoover, MS, MBA, Executive Vice President & Chief Administrative Officer, Faculty Physicians, led the development of this initiative in partnership with Dr. Regine and other physician leaders. "The faculty practice is committed to long-standing and transformative partnerships in our community that will enhance the health of our neighbors and our patients," said Ms. Hoover . "We plan to develop a multi-service centralized health care delivery model to improve primary care, chronic disease management, and care coordination between providers and their patients." The long-term vision for the community health village is for the Faculty Practice to expand West Baltimore partnerships with federally qualified health centers. This will further improve patient access and student-supported clinics at the Village at Mondawmin. Dental services may be offered in the newly leased space with faculty from the University of Maryland School of Dentistry. There is also the potential for an expansion of services provided by other faculty within UMB, including the schools of nursing, social work, law, graduate, and pharmacy. "UMB is committed to preparing the next generation of health care and human services professionals. At the same time, as an anchor institution in West Baltimore, we are also committed to supporting community health and well-being," said Bruce E. Jarrell, MD, FACS, President of the University of Maryland, Baltimore. "Just as our students' service can help address critical health equity issues, we know their professional development will be enriched by their experiences here working with our neighbors." About The Village at Mondawmin In March of 2022 Tim Regan, Whiting-Turner president and CEO, and his wife Joanne purchased the former Mondawmin Mall Target store with the aim of creating an active community hub that would help revitalize the historic West Baltimore neighborhood and Mondawmin Mall. Prior to this acquisition, Regan and President and CEO of Exelon Calvin Butler co-founded Mondawmin's TouchPoint Baltimore - now a tenant at The Village at Mondawmin - a unique collaboration space developed and funded exclusively by Whiting-Turner and BGE that is now home to several nonprofit organizations. Like TouchPoint Baltimore, the nearly 125,000 square foot space, now named The Village at Mondawmin is being developed in consultation with local community leaders with the goal to unlock untapped talent in the neighborhoods of West Baltimore and advance growth within the city. For more information visit About the University of Maryland School of Medicine Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System ("University of Maryland Medicine") has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu. Provided by Newswise, online resource for knowledge-based news at SOURCE University of Maryland School of Medicine